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Background: Knowledge is increasing about TSC-Associated Neuropsychiatric
Disorders (TAND), but little is known about the potentially confounding effects of
intellectual ability (IA) on the rates of TAND across age, sex, and genotype. We evaluated
TAND in (a) children vs. adults, (b) males vs. females, and (c) TSC1 vs. TSC2 mutations,
after stratification for levels of IA, in a large, international cohort.
Methods: Individuals of any age with a documented visit for TSC in the 12
months prior to enrolment were included. Frequency and percentages of baseline
TAND manifestations were presented by categories of IA (no intellectual disability [ID,
intelligence quotient (IQ)>70]; mild ID [IQ 50–70]; moderate-to-profound ID [IQ<50]).
Chi-square tests were used to test associations between ID and TAND manifestations.
de Vries et al. TAND Profiles and Intellectual Ability
The association between TAND and age (children vs. adults), sex (male vs. female),
and genotype (TSC1 vs. TSC2) stratified by IA levels were examined using the
Cochran–Mantel–Haenszel tests.
Results: Eight hundred and ninety four of the 2,211 participants had formal IQ
assessments. There was a significant association (P < 0.05) between levels of IA and the
majority of TAND manifestations, except impulsivity (P = 0.12), overactivity (P = 0.26),
mood swings (P = 0.08), hallucinations (P = 0.20), psychosis (P = 0.06), depressive
disorder (P = 0.23), and anxiety disorder (P = 0.65). Once controlled for IA, children
had higher rates of overactivity, but most behavioral difficulties were higher in adults. At
the psychiatric level, attention deficit hyperactivity disorder (ADHD) was seen at higher
rates in children while anxiety and depressive disorders were observed at higher rates in
adults. Compared to females, males showed significantly higher rates of impulsivity and
overactivity, as well as autism spectrum disorder (ASD) and ADHD. No significant age
or sex differences were observed for academic difficulties or neuropsychological deficits.
After controlling for IA no genotype-TAND associations were observed, except for higher
rates of self-injury in individuals with TSC2 mutations.
Conclusions: Findings suggest IA as risk marker for most TAND manifestations. We
provide the first evidence of male preponderance of ASD and ADHD in individuals with
TSC. The study also confirms the association between TSC2 and IA but, once controlling
for IA, disproves the previously reported TSC2 association with ASD and with most other
TAND manifestations.
Keywords: intelligence quotient, tuberous sclerosis complex, TSC-associated neuropsychiatric disorders, TOSCA,
TAND profile
INTRODUCTION
Tuberous sclerosis complex (TSC) is a genetic disorder with
prevalence of 1:5,800 live births. It is caused by mutation in
either the TSC1 or TSC2 gene and characterized by the growth
of benign hamartomas in multiple organs including the brain,
and is often associated with a high rate of neurological deficits
(1). Apart from the range of physical manifestations observed,
around 90% of patients with TSC exhibit some neuropsychiatric
manifestations and these are associated with the greatest burden
of care for families (1–5). Although most people with TSC will
have neuropsychiatric disorder, only a small proportion typically
ever receive screening, diagnosis, and treatment for these (6).
The term TAND (TSC-associated neuropsychiatric disorders)
was therefore coined to capture the multi-level manifestations,
and a TAND Checklist was developed as a simple screening
tool to help in the identification and prioritization of TAND
manifestations (7, 8).
TAND manifestations are classified into 6 levels
including behavioral, psychiatric, intellectual, academic,
neuropsychological, and psychosocial levels (3). Among
behavioral difficulties, the reported ranges to date include
depressed mood (19–43%), anxiety (41–56%), self-injury
(17–69%), aggression (37–66%), temper tantrums (47–70%),
overactivity/hyperactivity (22–73%), impulsivity (36–62%), and
sleep difficulties (15–74%) (6, 9–11). At the psychiatric level,
reported rates include autism spectrum disorder (ASD; 40–50%),
attention deficit hyperactivity disorder (ADHD; 30–40%),
anxiety and depressive disorder (27–56%) and psychosis (2.3%)
(1, 6, 9). At the intellectual level, around 40–50% of individuals
with TSC are considered to have normal intellectual ability (IA),
and the remaining have some degree of intellectual disability
(ID) (2, 12, 13). The majority of individuals with TSC have had
difficulties in academic or scholastic skills (2). Individuals with
TSC are at high risk of a range of neuropsychological deficits
including attention deficits, memory deficits, and executive
deficits. At the psychosocial level, family stress and difficulties
with self-esteem and self-efficacy are often reported (3, 14).
The etiology of TAND manifestations has received some
scientific investigation over the last few decades. It is well-
established that epilepsy (infantile spasms and other seizure
types) is a clear risk marker for many TAND manifestations,
particularly intellectual ability (1, 15, 16). The role of structural
brain abnormalities such as cortical tubers or SEGA has been
less clear (1, 3, 17). Direct molecular models suggesting that
the functional consequences of TSC1 or TSC2 mutations may
directly lead to TAND, and combinatorial models of the above,
have also been suggested (1, 18).
Given the relative rarity of TSC, the evidence-base for TAND
manifestations and their patterns have, until recently, been based
on relatively small-scale studies that typically examined only
some of the levels of TAND, and that were typically from a
single country. Very little was known about the differences
between children and adults or between those with TSC1 vs.
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TSC2 mutations. In a recent study, we evaluated TAND in a
large multicenter international study (TOSCA) and examined
profiles of manifestations in children vs. adults, in different
age-bands, and in those with TSC1, TSC2, and no mutation
identified (NMI) (2). Findings in the study were based on
data from 2,216 participants at the third interim analysis (cut-
off 30 September 2015) of the TOSCA natural history study.
The study showed significantly higher rates of overactivity and
impulsivity in children and higher rates of anxiety, depressed
mood, mood swings, obsessions, psychosis, and hallucinations in
adults. Individuals with TSC2 mutations had higher frequency
of self-injury, ASD, academic difficulties and neuropsychological
deficits, while those with NMI showed a mixed pattern of TAND
manifestations. Interestingly, individuals with TSC1 mutations
showed higher rates of impulsivity, anxiety, depressed mood,
hallucinations, psychosis, and of ADHD, anxiety and depressive
disorders (2).
A key finding from the study was the observation that
those with TSC2 mutations had significantly higher rates of ID.
Intellectual ability is known to be a strong correlate or riskmarker
of behavioral, psychiatric, academic, and neuropsychological
deficits both in general population and in individuals with
TSC (6, 19). For example, an earlier study in 265 children
and adolescents with TSC showed differential rates of many
behavioral manifestations, ASD and ADHD, in individuals with
and without ID (6). The fundamental role of IA as risk marker for
TAND therefore raises concerns about the previous findings of
de Vries and colleagues (2) in terms of child vs. adult differences,
and about TSC1 vs. TSC2 differences in TAND.
It is also well-established that many psychopathologies have
been associated with differential rates between male and females.
For example, boys and men are typically associated with higher
rates of ASD and ADHD, while girls and women are typically
associated with higher rates of anxiety and mood disorders
(20–24). Studies in TSC to date have shown conflicting findings
in relation to sex differences of TAND. In one small study from
Wessex, UK a significant male preponderance in the rates of
ID was reported (25). In contrast, other studies have shown
no difference in the rates of behavioral problems, psychiatric
disorders or ID (6, 26). To date no studies have compared
academic/scholastic difficulties and neuropsychological deficits
between male and female individuals with TSC.
Here, we therefore set out to perform a detailed exploration
of the association of TAND manifestations (a) between children
and adults, (b) between males and females, and (c) between
those with TSC1 and TSC2 mutations, in a large international
sample of individuals with TSC, stratified for their levels of
IA. We hypothesized that, after controlling for levels of IA (a)
the significant differences observed between children and adults
would be maintained (2), (b) that, as per previous TSC research
no sex differences would be observed in TAND (6, 26), and (c)
that the TSC1-TSC2 differences observed in our earlier study
would be maintained (2).
PARTICIPANTS AND METHODS
TOSCA, a multicenter, international study in individuals with
TSC, was conducted at 170 sites in 31 countries. The study
methodology of TOSCA has been detailed previously (27). In
brief, the study consisted of a core section and 6 ancillary research
projects, focusing each on subependymal giant cell astrocytomas
(SEGA), renal angiomyolipoma and lymphangiomyomatosis,
genetics, TAND, epilepsy, and quality of life. TAND data
were collected from retrospective and prospective information
available to study clinicians using a standardized data recording
sheet as part of the case report form (CRF). The TAND data
recording sheet were a precursor of the TAND Checklist (8).
Comprehensive data were collected at baseline and annually
thereafter for up to 5 years. Interim analyses of all data collected
were done annually. Here we present results of the final analysis
(last patient last visit, 10 August 2017).
All TOSCA participants in the final analysis with formal IQ
assessment data were included in this study. Frequency and
percentages of baseline TAND manifestations were presented by
categories of IA [intelligence quotient (IQ) >70= no ID (noID);
IQ= 50–70=mild ID (MID); IQ <50=moderate-to-profound
ID (M-PID)]. Chi-square test was used to examine the association
between ID and TAND manifestations. The association between
TAND and age [children [aged ≤18 years] vs. adults [aged >18
years]], sex (male vs. female), and genotype (TSC1 vs. TSC2)
stratified by IA (noID, MID, M-PID) was examined using the
Cochran–Mantel–Haenszel tests. Statistical significance was set
at p < 0.05.
The study was designed and conducted in accordance with the
Good Clinical Practice principles, the Declaration of Helsinki,
and all the local regulations. The Institutional Review Board
or Ethics Committee at each participating center approved
all the TOSCA related documents. Written informed consent
was obtained from all participants, parents, or guardians prior
to enrolment.
RESULTS
Overall 2,214 participants with TSC were enrolled into the
TOSCA registry from 170 sites across 31 countries. Of these, data
of 2,211 eligible participants were analyzed. Data of 3 participants
were excluded from the analysis due tomajor protocol deviations.
Of the 2,211 participants, 894 (40.4%) had formal IQ assessments;
395 had normal IQ, 251 had MID and 248 had M-PID. Baseline
demographics of this cohort were similar to that of the overall
cohort and those without IQ (Table 1).
Overall TAND Manifestations and Their
Association With Levels of Intellectual
Ability (IA)
The overall and stratified frequencies of TANDmanifestations in
the final TOSCA cohort are depicted in Table 2. The majority of
behavioral difficulties showed significant association (P < 0.05)
with the levels of IA, except impulsivity (P = 0.12), overactivity
(P = 0.26), mood swings (P = 0.08), hallucinations (P = 0.20),
and psychosis (P = 0.06, Table 2). IA showed a significant
association with ASD, ADHD, and other psychiatric disorders,
but not with depressive disorder (P = 0.23) or anxiety disorder
(P = 0.65). Academic difficulties and neuropsychological deficits
were significantly associated with levels of IA (Table 2).
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TABLE 1 | Demographics of participants in the TOSCA study.
Characteristics Overall Cohort
(N = 2,211)
Participants with
IQ assessments
(N = 894)
Participants without
IQ assessments
(N = 1,305)
Age at TSC diagnosis,a years, median (range) 1.0 (0–69) 1.0 (0–60) 1 (0–69)
Gender, n (%)
Males 1059 (47.9) 432 (48.3) 621 (47.6)
Females 1152 (52.1) 462 (51.7) 684 (52.4)
Genetic molecular testing performed, n (%) 1011 (45.7) 468 (52.3) 543 (41.6)
Genetic testing, n (%)
No mutation identified 148 (14.6) 69 (14.7) 79 (14.5)
TSC1 mutation 191 (18.9) 94 (20.1) 97 (17.9)
TSC2 mutation 649 (64.2) 301 (64.3) 348 (64.1)
Both TSC1 and TSC2 mutation 5 (0.5) 0 5 (0.9)
Data not available 18 (1.8) 4 (0.8) 14 (2.6)
Mutation variation typeb, n (%)
Only pathogenic mutation 663 (65.6) 331 (70.7) 332 (61.1)
Only variant of unknown significance 43 (4.3) 18 (3.8) 25 (4.6)
Time from TSC diagnosis to molecular testing,
months, mean (SD)
81.8 (116.58) 84 (99.84) 79.8 (129.78)
Participants with prenatal diagnosis, n (%) 154 (7.0) 64 (7.2) 90 (6.9)
Participants with biological parent diagnosed with TSC, n (%)
Mother 184 (19.5) 95 (18.3) 98 (21.4)
Father 130 (15.7) 63 (14.9) 67 (16.6)
IQ, intelligence quotient; SD, standard deviation; TSC, tuberous sclerosis complex. aData available for 2,054 participants in the overall cohort. bThe count (n) also includes 23 participants
who had both mutation types.
TAND Manifestations in Children vs. Adults
Stratified by Intellectual Ability (IA)
Once controlled for IA, adults showed significantly higher
rates of most behavioral difficulties in comparison to children
(P < 0.05), including severe aggression, self-injury, anxiety,
mood swings, hallucination, obsession, and psychosis. Children
showed significantly higher rates only of overactivity (P < 0.05,
Figure 1A). No differences were observed between children and
adults on sleep difficulties (P = 0.99), impulsivity (P = 0.08) or
severe aggression (P = 0.10). At the psychiatric level, the rate of
ASD (P = 0.10) was not significantly different between children
and adults (Figure 1B). In contrast, ADHD (P < 0.05) were seen
at higher rates in children, while anxiety disorders, depressive
disorders and other psychiatric disorders were observed at higher
rates in adults. No significant differences were seen in the rates of
academic difficulties (Figure 1C) or neuropsychological deficits
(Figure 1D) between children and adults in IQ-stratified groups
(Supplementary Table 1).
TAND Manifestations in Males vs. Females
Stratified by Intellectual Ability (IA)
Two behavioral manifestations (impulsivity and overactivity)
were seen at significantly higher rates in males than females,
while anxiety rates were higher in females (Figure 2A,
Supplementary Table 2). No other behavioral manifestations
were statistically significantly different between males and
females once controlled for IA. At the psychiatric level, ASD
and ADHD were seen at significantly higher rates in males than
females, but depressive, anxiety and other psychiatric disorders
were not significantly different (Figure 2B). No differences were
observed between males and females in academic difficulties
(Figure 2C) or neuropsychological deficits (Figure 2D).
TAND Manifestations in TSC1 vs. TSC2
Stratified by Intellectual Ability (IA)
After controlling for levels of IA, only one of all the TAND
manifestations (self-injury) was observed at significantly
higher rates in patients with TSC2 mutations vs. those with
TSC1 mutations. No genotype-TAND associations were
seen on any other behavioral manifestations (Figure 3A,
Supplementary Table 3), psychiatric disorders (Figure 3B),
academic difficulties (Figure 3C) or neuropsychological deficits
(Figure 3D). In particular, the previously reported association
between TSC2 mutations and ASD was not statistically
significant (P = 0.09).
DISCUSSION
In this study we set out to examine TAND manifestations
in relation to age, sex, and genotype in an IA-stratified
sample of individuals from 31 countries. The large-scale cohort
allowed us to perform analyses not previously possible. In
the overall cohort of 894 participants who had formal IQ
evaluations, IA was significantly associated with the majority of
behavioral manifestations, apart from impulsivity, overactivity,
mood swings, hallucinations, and psychosis. In a similar pattern
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TABLE 2 | TAND manifestations in all participants with available IQ data stratified by levels of intellectual ability (noID [IQ>70], MID [IQ 50–70] and M-PID [IQ<50]).
TAND manifestation All participants with Level of intellectual ability P-valuea
IQ data available NoID (n = 395) MID (n = 251) M-PID (n = 248)
(N = 894) n (%) n (%) n (%)
n (%)
Behavioral level
Sleep difficulties 172 (40.3) 46 (31.9) 45 (34.9) 81 (52.6) 0.0004
Severe aggression 100 (23.3) 22 (15.6) 37 (27.2) 41 (26.8) 0.03
Self-injury 63 (14.7) 8 (5.7) 14 (10.6) 41 (26.1) <0.0001
Impulsivity 201 (47.2) 57 (40.7) 70 (53.0) 74 (48.1) 0.12
Overactivity 191 (44.4) 55 (39.0) 65 (48.5) 71 (45.8) 0.26
Depressed mood 76 (18.3) 37 (26.1) 27 (21.3) 12 (8.2) 0.0003
Anxiety 146 (34.9) 56 (40.0) 54 (40.3) 36 (25.0) 0.009
Mood swings 134 (32.3) 36 (26.3) 50 (39.1) 48 (32.0) 0.08
Obsessions 71 (17.1) 10 (7.2) 26 (20.0) 35 (24.1) 0.0004
Hallucinations 18 (4.3) 5 (3.5) 9 (7.0) 4 (2.8) 0.20
Psychosis 25 (6.0) 3 (2.1) 11 (8.3) 11 (7.6) 0.06
Psychiatric level
Autism spectrum disorder (ASD) 165 (21.0) 14 (4.0) 31 (14.2) 120 (55.6) <0.0001
Attention deficit hyperactivity disorder (ADHD) 167 (22.2) 56 (16.0) 55 (25.5) 56 (29.9) 0.0004
Depressive disorder 42 (5.7) 23 (6.7) 13 (6.3) 6 (3.2) 0.23
Anxiety disorder 87 (11.7) 38 (11.0) 28 (13.5) 21 (11.1) 0.65
Other psychiatric disorder 61 (8.2) 17 (4.9) 20 (9.6) 24 (12.6) 0.005
Academic level
Participants with academic/scholastic difficulties 450 (68.0) 143 (47.2) 156 (82.5) 151 (88.8) <0.0001
Participants assessed for difficulties 290 (76.9) 96 (75.0) 103 (79.8) 91 (75.8) 0.62
Neuropsychological level
Participants assessed for neuropsychological skills 408 (58.1) 183 (56.5) 123 (60.9) 102 (58.0) 0.61
Participants with any deficit (Performance<5th percentile) 250 (69.6) 69 (41.3) 92 (90.2) 89 (98.9) <0.0001
Values are expresses as number (%). Percentages are calculated excluding missing/unknown data.
IQ, intelligence quotient; noID, no intellectual disability; MID, mild intellectual disability; M-PID, moderate-to-profound intellectual disability; TAND, tuberous sclerosis complex-associated
neuropsychiatric disorders.
aP-value calculated from chi-square to test the association between categories of intellectual disability (NoID, MID and M-PID) and presence of respective TAND manifestation.
at the psychiatric level, IA was associated with ASD, ADHD, and
other psychiatric disorders, but not with depressive disorders or
anxiety disorders. Academic difficulties and neuropsychological
deficits showed a clear association with the levels of IA.
In terms of differences between children and adults, we
predicted that all age-related TAND manifestations previously
observed (2) would be maintained in stratified groups. In the
earlier study overactivity, impulsivity and ADHD were more
prominent in children, while anxiety, mood swings, depressed
mood, psychosis, hallucinations, depressive disorder, and anxiety
disorder were more prominent in adults. After controlling for
IA, only overactivity was observed at significantly a higher rate
in children, while most other behavioral manifestations had
higher rates in adults. These observations challenge previous
data that suggested an improvement or reduction in behavioral
difficulties in individuals with TSC over time. In keeping
with general population patterns, even after IA stratification,
ADHD was observed at higher rates in children, and depressive
and anxiety disorders at higher rates in adults. No academic
difficulties or neuropsychological deficits showed age-based
patterns after stratification. Mindful of the fact that these findings
are based on cross-sectional rather than longitudinal data, our
results suggest the need for careful longitudinal examination of
behavioral change and emergence of psychopathology over time
in TSC.
We predicted that, based on previous TSC research (6, 26), no
sex differences would be observed. Contrary to the hypothesis,
impulsivity, overactivity, anxiety, and obsessions, as well as ASD
and ADHD were significantly more common in males. These
observations are therefore the first clear evidence of a sex-
related preponderance of ASD, ADHD and related behavioral
manifestations in TSC. Anxiety symptoms were observed at
higher rates in females, but, interestingly, no sex differences were
observed in rates of anxiety disorders. Findings suggest that,
at least for some psychopathologies in TSC, sex may play a
contributory role. Future research should therefore consider the
potential role of sex alongside genetic and other environmental
factors in the pathway to psychopathology in TSC. Our results
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FIGURE 1 | Frequency of TAND features stratified by levels of intellectual ability (noID [IQ>70], MID [IQ 50–70] and M-PID [IQ<50]) in children vs. adults. (A)
Behavioral difficulties. (B) Psychiatric disorders. (C) Academic difficulties. (D) Neuropsychological deficits. Percentages calculated excluding missing/unknown data.
certainly highlight the need to control for sex in any comparative
studies involving individuals with TSC.
Given previous reports of an association between TSC2 and
more severe TSC manifestations, we predicted the same pattern
for TAND. We observed a clear correlation between levels of IA
and genotype, with TSC2 more likely to be associated with ID.
However, after controlling for levels of IA, only one of all the
genotype-TAND correlations was statistically significant (self-
injury, P = 0.0496). We are cautious not to over-interpret what
might have been a spurious finding. Importantly, the previously
suggested association between TSC2 mutations and ASD was
not replicated in our data. These results support the previous
evidence of the strong association between levels of intellectual
ability and psychopathologies in the general population (28, 29),
and provide the first clear evidence of the association between IA
and all levels of TAND investigated here. However, our findings
did not suggest a specific association between TSC1 or TSC2 and
TAND once levels of IA had been controlled for. Our findings
therefore underline the importance of controlling for the levels
of IA in any future study that may wish to compare or contrast
TAND in individuals with TSC1 and TSC2mutations.
Overall our findings underline the prominent role of IA as a
risk marker for TAND manifestations, illustrated the differences
in TAND profiles between children and adults over and above
IA, and, for the first time, identified male sex as an additional
risk marker for TAND. Together, these highlight the need always
to consider intellectual ability, age, and sex in any TAND-related
research investigation.
Implications for Clinical Practice
The findings reported here support the value of an intellectual
ability evaluation of all individuals with TSC. Even though
we reported the largest cohort with formal IQ assessments
to date (n = 894), this represented only 40.4% of the
overall TOSCA cohort. Even in expert TSC centers, IQ was
therefore not routinely evaluated. With regards to age-related
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changes, overactivity showed lower rates in adults, but the
majority showed higher rates in adults stratified by IA. It
will be important not to interpret this as “worsening” of
behaviors in adults with TSC given that our dataset was cross-
sectional. Longitudinal studies will be important to examine
this aspect, but, for clinical practice, results suggest that not
all behavioral manifestations may always improve. The clear
increase in mood and anxiety symptoms and disorders into
adulthood emphasizes the dynamic nature of TAND, and
underlines the importance of annual screening for TAND
using tools such as the TAND Checklist, as recommended
in the International Consensus Guidelines (8, 30). The sex
differences observed with higher rates of ASD and ADHD
in males with TSC are in keeping with general population
observations, and raise interesting scientific questions. From
a clinical perspective, even though some sex differences were
observed, it is also clear that all males and females should
be monitored for all TAND manifestations. At a clinical
level the absence of genotype-TAND correlations suggests that,
apart from the greater likelihood of ID in association with
TSC2, clinicians should not suggest to families to expect
significantly different TAND profiles in an individual with
TSC1 vs. TSC2. All individuals with TSC should therefore be
screened andmonitored for all TANDmanifestations throughout
their lifespan.
Limitations
We acknowledge the limitations intrinsic to a large-scale,
international, non-interventional/observational study. These
included the fact that participants were recruited from expert
TSC centers around the world, included evaluation in a range of
languages, and the fact that evaluations were performed based
on standard clinical practice in each center, rather than on
a pre-specified set of evaluation instruments. However, these
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limitations are, at least in part, off-set by the large-scale and “real-
world” nature of the cohort across multiple centers and countries.
We acknowledge the high proportion of non-reported (missing)
data by sites, including IA evaluation on only 40.4% of the cohort.
This finding emphasizes that, even in expert TSC centers, TAND
manifestations are often not examined and therefore not treated.
We also acknowledge that we focused here on the association
between intellectual ability, age, sex, and genotype and that
we did not include the potential contributions of physical risk
markers (e.g., seizures, SEGA or other TSC manifestations) into
our modeling of associations.
CONCLUSION
The TOSCA study confirmed the association between levels of
IA and TAND manifestations, suggesting IA as risk marker for
most TAND manifestations and provided the first evidence of
a male preponderance of ASD and ADHD in individuals with
TSC. The study also confirmed the association between TSC2
and IA but disproved the previously reported TSC2 association
with ASD and most other TAND manifestations once controlled
for IA. Overall, the study reinforces the high frequency of
TAND manifestations in all individuals with TSC across age,
sex, and genotype, and strengthens the evidence-base for regular
screening, comprehensive evaluation and intervention for the
dynamic and variable range of neuropsychiatric manifestations
associated with TSC.
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